Pharma Boardroom Interview
Interview for Pharma Boardroom, discussing the Institute Gulbenkian de Ciência – Fundação Calouste Gulbenkian.
Similar Posts
Rebuilding the Case for Diagnostics Investment (1/2): Reflections and Notes for Founders
Published on LinkedIn on Nov 17th The diagnostics sector faces a paradox: we’re living through a precision medicine revolution, yet the tools that make precision medicine possible remain chronically underfunded. In 2023-2024, diagnostics captured just $2.2 billion in global venture funding, while AI companies raised over $100 billion globally in 2024. Even within healthcare, nearly…
Rebuilding the Case for Diagnostics Investment (2/2): A Framework for Investors
Published on LinkedIn on Nov 20th In Part 1/2 (https://www.linkedin.com/pulse/rebuilding-case-diagnostics-investment-12-reflections-pereira-leal-swvbf), I discussed why diagnostics face a systematic funding gap despite being essential infrastructure for precision medicine, and outlined five strategic directions for entrepreneurs building diagnostic companies. Those reflections emerged from building Ophiomics and follow from the reflection I’ve been making for my book, Precision Diagnostics:…
The Diagnostic Timing Trap
“70% of clinical decisions depend on diagnostics.” You’ve seen this statistic, but it hides an important detail: timing. The acuity gradient: Lab testing occurs in 98% of inpatient encounters, 56% in emergency departments, but only 29% in outpatient settings (Ngo et al., 2017): diagnostics concentrate where disease is most advanced. Prevention is neglected: Evidence-based guidelines…
Entevista – SAPOLifestyle
BIÓPSIA LÍQUIDA, O “SANTO GRAAL” DA MEDICINA QUE É BARATO E EFICAZ NA DETEÇÃO DO CANCRO A biópsia líquida é um exame médico padronizado que tem ganho atenção científica mas também mediática pelas suas potencialidades na deteção precoce de várias doenças, nomeadamente as patologias oncológicas. Estivemos à conversa com o investigador José Leal, diretor executivo…
Movimento Ciência Portugal – 2011
Following the election of new government, and at the onset of a major financial crisis that lasts to these days, some of us (scientists) were very worried by a shift in funding of science from basic to applied. It was (and is) our conviction that without a solid foundation in basic science no disruptive innovation…
New drugs for biodefense with bioinformatics
Years ago I supervised a research project on genome reduction in bacteria, in obligate intracellular parasites and endosymbionts. We (myself, André Mendonça and Renato Alves), after an extensive exercise in genome data analysis and genome evolution modelling, realised that environmental predictability was a major force driving genome reduction. To this day, this is probably the…